Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.47
IMRS's Cash to Debt is ranked higher than
58% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.81 vs. IMRS: 0.47 )
IMRS' s 10-Year Cash to Debt Range
Min: 0.3   Max: No Debt
Current: 0.47

Equity to Asset 0.30
IMRS's Equity to Asset is ranked higher than
52% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. IMRS: 0.30 )
IMRS' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.86
Current: 0.3

0.3
0.86
F-Score: 3
Z-Score: -0.87
M-Score: -3.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -85.37
IMRS's Operating margin (%) is ranked higher than
50% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. IMRS: -85.37 )
IMRS' s 10-Year Operating margin (%) Range
Min: -180.07   Max: -1.01
Current: -85.37

-180.07
-1.01
Net-margin (%) -91.22
IMRS's Net-margin (%) is ranked higher than
50% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.98 vs. IMRS: -91.22 )
IMRS' s 10-Year Net-margin (%) Range
Min: -184.84   Max: -2.02
Current: -91.22

-184.84
-2.02
ROE (%) -119.93
IMRS's ROE (%) is ranked lower than
52% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. IMRS: -119.93 )
IMRS' s 10-Year ROE (%) Range
Min: -119.93   Max: -1.55
Current: -119.93

-119.93
-1.55
ROA (%) -49.09
IMRS's ROA (%) is ranked higher than
50% of the 299 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. IMRS: -49.09 )
IMRS' s 10-Year ROA (%) Range
Min: -54.44   Max: -1.26
Current: -49.09

-54.44
-1.26
ROC (Joel Greenblatt) (%) -119.71
IMRS's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 297 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.48 vs. IMRS: -119.71 )
IMRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -531.98   Max: -4.94
Current: -119.71

-531.98
-4.94
Revenue Growth (%) -22.20
IMRS's Revenue Growth (%) is ranked higher than
51% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. IMRS: -22.20 )
IMRS' s 10-Year Revenue Growth (%) Range
Min: -22.2   Max: 65.3
Current: -22.2

-22.2
65.3
EPS Growth (%) 163.40
IMRS's EPS Growth (%) is ranked higher than
99% of the 242 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. IMRS: 163.40 )
IMRS' s 10-Year EPS Growth (%) Range
Min: -59.8   Max: 163.4
Current: 163.4

-59.8
163.4
» IMRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with IMRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.40
IMRS's P/B is ranked higher than
74% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. IMRS: 2.40 )
IMRS' s 10-Year P/B Range
Min: 1.2   Max: 13.95
Current: 2.4

1.2
13.95
P/S 1.30
IMRS's P/S is ranked higher than
88% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. IMRS: 1.30 )
IMRS' s 10-Year P/S Range
Min: 1.12   Max: 6.51
Current: 1.3

1.12
6.51

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.40
IMRS's Price/Tangible Book is ranked higher than
85% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.39 vs. IMRS: 2.40 )
IMRS' s 10-Year Price/Tangible Book Range
Min: 1.47   Max: 31.05
Current: 2.4

1.47
31.05
Price/Median PS Value 0.40
IMRS's Price/Median PS Value is ranked higher than
98% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. IMRS: 0.40 )
IMRS' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 1.88
Current: 0.4

0.43
1.88
Earnings Yield (Greenblatt) 0.20
IMRS's Earnings Yield (Greenblatt) is ranked lower than
55% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. IMRS: 0.20 )
IMRS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 2.1
Current: 0.2

0.2
2.1
Forward Rate of Return (Yacktman) -40.83
IMRS's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 260 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.14 vs. IMRS: -40.83 )
IMRS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 22.3   Max: 55.8
Current: -40.83

22.3
55.8

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare: » details
Traded in other countries:IM.Canada, 9IM.Germany
IMRIS, Inc., was incorporated on May 18,2005 under the Canada Business Corporations Act. The Company designs, manufactures and markets the VISIUS Surgical TheatreTM, a multifunctional surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. It also provides ancillary products and services and extended maintenance services. Designed to meet each hospital's specific clinical application needs, the VISIUS Surgical Theatre can incorporate MR imaging, CT imaging and x-ray angiography in a number of configurations to provide intraoperative images of diagnostic quality without introducing additional patient transport risk and delivering real-time information to clinicians while preserving optimal surgical access and techniques. The Company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, cerebrovascular and cardiovascular markets.
» More Articles for NAS:IMRS

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest volume increases Aug 27 2014
8:10 am IMRIS announces that recently published article in the journal Neurosurgery is the highest... Aug 26 2014
Highest level evidence published in Neurosurgery journal indicates better outcomes when using iMRI Aug 26 2014
Highest level evidence published in Neurosurgery journal indicates better outcomes when using iMRI Aug 26 2014
IMRIS receives Health Canada licensing for integrating latest generation MR scanners within VISIUS... Aug 21 2014
IMRIS receives Health Canada licensing for integrating latest generation MR scanners within VISIUS... Aug 21 2014
IMRIS intraoperative imaging moving system and coils patents granted in Japan Aug 13 2014
IMRIS intraoperative imaging moving system and coils patents granted in Japan Aug 13 2014
IMRIS Reports Second-Quarter 2014 Financial Results Aug 07 2014
IMRIS Reports Second-Quarter 2014 Financial Results Aug 07 2014
Wall Street Transcript Interview with Jay D. Miller, the President and CEO of IMRIS Inc. (IMRS) Aug 01 2014
IMRIS CEO Jay D. Miller to present at InvestMNt 2014 Conference Jul 31 2014
IMRIS CEO Jay D. Miller to present at InvestMNt 2014 Conference Jul 31 2014
IMRIS to hold second quarter 2014 results conference call Jul 29 2014
IMRIS to hold second quarter 2014 results conference call Jul 29 2014
IMRIS receives CE mark for integrating latest generation MR scanners within VISIUS Surgical Theatre... Jul 23 2014
IMRIS receives CE mark for integrating latest generation MR scanners within VISIUS Surgical Theatre... Jul 23 2014
5 Stocks Under $10 Set to Soar Jun 19 2014
3 Stocks Under $10 Making Big Moves Jun 19 2014
Largest published study shows pituitary tumor removal improved by iMRI and endoscopy together Jun 04 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK